The global medical technology company Mölnlycke has announced plans to separate its Operating Room Solutions and Gloves businesses into a standalone company, with the transaction expected to be completed in 2027.
The new company, Mölnlycke Surgical, will comprise the two businesses, while Mölnlycke will continue to operate its Wound Care and Antiseptics businesses.
Both companies will operate as standalone portfolio companies under the ownership of Patricia Industries, subject to customary approvals.
The separation follows a review of Mölnlycke’s business portfolio, with the company’s board citing changes in market dynamics, customer needs and value drivers.
In 2025, the Operating Room Solutions and Gloves businesses generated approximately €800m in net sales, with an EBITDA margin of around 11%.
Wound Care and Antiseptics recorded approximately €1.3bn in net sales and an EBITDA margin of around 38%.
Mölnlycke said the new structure would allow the two companies to focus on their respective markets.
Mölnlycke Surgical will focus on surgical efficiency, safety and outcomes, while Mölnlycke will concentrate on innovation and investment in Wound Care and Antiseptics.
The company said the capitalisation of both businesses would be assessed during the separation process to ensure they have resources suited to their needs.
It also intends to maintain Mölnlycke’s investment-grade credit rating.
The separation is expected to be completed in 2027, subject to customary approvals.
“We are making this move from a position of strength. Greater focus will allow both companies to move faster, invest with greater clarity and respond more effectively to evolving customer needs,” said Guillaume Joucla, Interim CEO of Mölnlycke.
